Profile data is unavailable for this security.
About the company
Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its pharmaceutical products include chemically synthesized or small molecule drugs and products produced from biological processes, called biologics. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. It also has a pipeline of investigational medicines designed to target the common mutations associated with oncogenesis, including repotrectinib. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.
- Revenue in USD (TTM)46.74bn
- Net income in USD6.68bn
- Incorporated1933
- Employees32.20k
- LocationBristol-Myers Squibb Co430 E. 29Th Street, 14 FloorNEW YORK 10016United StatesUSA
- Phone+1 (212) 546-4000
- Fax+1 (302) 655-5049
- Websitehttps://www.bms.com/
Mergers & acquisitions
| Acquired company | BMY:NYQ since announced | Transaction value |
|---|---|---|
| Turning Point Therapeutics Inc | 7.63% | 4.08bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. | 27.14bn | 3.33bn | 111.67bn | 14.40k | 33.67 | 5.30 | 20.61 | 4.12 | 2.64 | 2.64 | 21.52 | 16.81 | 0.4186 | 4.39 | 6.08 | 1,884,445.00 | 5.10 | 8.35 | 6.07 | 10.02 | 74.62 | 79.56 | 12.19 | 22.22 | 1.16 | 5.86 | 0.545 | 58.76 | 10.60 | -2.12 | 4,960.98 | -14.34 | -4.99 | 9.07 |
| Amgen, Inc. | 26.33bn | 6.84bn | 152.34bn | 24.20k | 22.87 | 41.70 | 14.95 | 5.79 | 12.48 | 12.48 | 48.09 | 6.85 | 0.4092 | 1.43 | 5.22 | 1,088,017.00 | 10.62 | 11.07 | 13.74 | 13.40 | 75.78 | 79.29 | 25.96 | 30.88 | 1.35 | 7.70 | 0.9138 | 49.28 | 2.18 | 2.47 | -18.87 | -5.26 | 1.01 | 11.97 |
| Bristol-Myers Squibb Co | 46.74bn | 6.68bn | 172.50bn | 32.20k | 26.45 | 5.27 | 10.13 | 3.69 | 3.07 | 3.07 | 21.53 | 15.38 | 0.4471 | 4.65 | 5.72 | 1,451,491.00 | 6.40 | 2.67 | 7.94 | 3.29 | 78.91 | 74.18 | 14.32 | 6.54 | 1.31 | 4.49 | 0.5443 | 163.84 | 9.09 | 19.01 | 177.58 | 9.43 | -4.35 | 5.22 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2022 | 190.97m | 8.98% |
| BlackRock Fund Advisorsas of 30 Sep 2022 | 112.66m | 5.30% |
| SSgA Funds Management, Inc.as of 30 Sep 2022 | 92.33m | 4.34% |
| JPMorgan Investment Management, Inc.as of 30 Sep 2022 | 63.34m | 2.98% |
| Capital Research & Management Co. (International Investors)as of 30 Sep 2022 | 52.40m | 2.46% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2022 | 51.60m | 2.43% |
| Geode Capital Management LLCas of 30 Sep 2022 | 39.15m | 1.84% |
| Wellington Management Co. LLPas of 30 Sep 2022 | 33.39m | 1.57% |
| Norges Bank Investment Managementas of 31 Dec 2021 | 22.68m | 1.07% |
| Managed Account Advisors LLCas of 30 Sep 2022 | 22.27m | 1.05% |
